Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01262729

Acronym

10-015

Enrollment

Registered

2010-12-17

Start date

2011-09-30

Completion date

2014-12-31

Last updated

2015-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addition to Therapeutical Hypothermia, Efficacy and Safety of Xenon Inhalation, Successful Cardiopulmonary Resuscitation

Keywords

xenon inhalation, therapeutical hypothermia, patients after cardiopulmonary resuscitation, efficacy, safety

Brief summary

In this clinical trial will be checked, whether 2 hour ventilation with xenon has neuroprotective effects in patients with out of hospital cardiac arrest and successful cardiopulmonary resuscitation

Detailed description

Patients with out of hospital cardiac arrest and successful cardiopulmonary resuscitation will be randomized in two groups. First group (Treatment group) will be inhalated with xenon within 2 hours in addition to therapeutical hypothermia. The second group (Control group) will be treated with therapeutical hypothermia in accordance to international guidelines.

Interventions

PROCEDUREtherapeutical hypothermia

Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)

DRUGXenon Inhalation

Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with out of hospital cardiac arrest and successful cardiopulmonary resuscitation, which will be treated at Department of Internal Medicine I, University Hospital Aachen

Exclusion criteria

* Patients younger than 18 years * Xenon allergy * Pregnancy * High expired oxygen requirement (\>70%) in order to maintain adequate arterial oxygen saturation (SpO2\>94%) at the beginning of treatment

Design outcomes

Primary

Measure	Time frame
Significant difference between treatment group and control group	within 28 days after cardiac arrest

Secondary

Measure	Time frame
Safety and efficacy of xenon ventilation within 2 hours after successful cardiopulmonary resuscitation	within 28 days after cardiac arrest

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026